EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Control Bionics's Enterprise Value is A$7.13 Mil.
Control Bionics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.52 Mil. Therefore, Control Bionics's EV-to-FCF for today is -1.58.
The historical rank and industry rank for Control Bionics's EV-to-FCF or its related term are showing as below:
ASX:CBL'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.27 Med: -1.36 Max: 1.11
Current: -1.35
During the past 4 years, the highest EV-to-FCF of Control Bionics was 1.11. The lowest was -8.27. And the median was -1.36.
ASX:CBL's EV-to-FCF is ranked worse than 100% of 362
companies
in the Medical Devices & Instruments industry
Industry Median: 27.855
vs ASX:CBL: -1.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Control Bionics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Control Bionics's EV-to-FCF
For the Medical Devices subindustry, Control Bionics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Control Bionics's EV-to-FCF falls into.
Control Bionics's current Enterprise Value is A$7.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Control Bionics's PE Ratio for today is calculated as:
Control Bionics's share price for today is A$0.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Control Bionics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Control Bionics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Control Bionics Ltd is engaged in the business of healthcare devices. It is engaged in the development, commercialization, and sale of assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:CBL has been successfully added to your